Novartis can’t appeal loss of experts in MS drug patent feud with Pharmacor
Appeals 2022-04-07 12:29 pm By Christine Caulfield | Melbourne
Please login to bookmark Close

The Full Federal Court won’t give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au